Silibinin ameliorates STZ-induced impairment of memory and learning by up- regulating insulin signaling pathway and attenuating apoptosis

• Published in: Physiology & behavior 2020-01, Vol.213, p.112689, Article 112689
• Main Authors: Liu, Panwen, Cui, Lingyu, Liu, Bo, Liu, Weiwei, Hayashi, Toshihiko, Mizuno, Kazunori, Hattori, Shunji, Ushiki-Kaku, Yuko, Onodera, Satoshi, Ikejima, Takashi
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Animals; Apoptosis - drug effects; Cerebral Cortex - metabolism; Cognitive Dysfunction - chemically induced; Cognitive Dysfunction - prevention & control; Diabetes Mellitus, Experimental - chemically induced; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Experimental - pathology; Diabetes Mellitus, Experimental - prevention & control; Hippocampus - pathology; Insulin - metabolism; Insulin signaling pathway; Insulin-Like Growth Factor I - metabolism; Male; Memory Disorders - chemically induced; Memory Disorders - prevention & control; Nerve Degeneration - chemically induced; Nerve Degeneration - pathology; Nerve Degeneration - prevention & control; Neuroprotective Agents - pharmacology; Phosphorylation - drug effects; Rats; Signal Transduction - drug effects; Silibinin; Silybin - pharmacology; Streptozocin - antagonists & inhibitors; Streptozotocin; tau Proteins - metabolism
• ISSN: 0031-9384; 1873-507X
• DOI: 10.1016/j.physbeh.2019.112689

•Silibinin significantly ameliorates STZ-caused cognitive and memory deficit.•Silibinin attenuates the neuronal loss and degeneration induced by STZ treatment.•Silibinin exerts a neuroprotective effect through inhibiting STZ-induced hyper-phosphorylation of tau proteins.•Silibinin can recover the function of insulin/IGF1 signaling pathway. Alzheimer's disease (AD) is a neurodegenerative disease, mainly characterized by cognitive dysfunction and memory impairment. Due to its pathological similarities to type 2 diabetes mellitus (T2DM), such as β-amyloid deposition, oxidative stress, inflammation, disordered glucose metabolism, impaired signaling pathways of insulin and insulin-like growth factor-1 (IGF-1), we speculate that AD is another form of brain diabetes. Clarifying the relationship between T2DM and AD is important for us to better understand the exact pathological mechanisms of AD. Silibinin, a polyphenolic flavonoid extracted from the seeds of Silybum marianum, exerts hepatoprotective, anti- diabetic and neuroprotective effects. Streptozotocin (STZ), which is used to disrupt the insulin signal transduction pathway, could well mimic the sporadic AD models by intracerebroventricular (ICV) injection. Therefore, we selected ICV injection of STZ (ICV-STZ) to investigate the neuroprotective effects of silibinin in rats and to make a foundation for further exploring the relationship between AD and T2DM. ICV-STZ obviously caused memory damage, sharply reduced the number of nissl bodies and destroyed morphological structure of hippocampal neuronal cells, while silibinin attenuated the damages. Moreover, silibinin significantly decreased STZ-induced tau hyperphosphorylation (ser404) in hippocampus and cerebral cortex, markedly inhibited apoptosis of neurons induced by STZ, and up-regulated insulin signal transduction pathway. Silibinin exerts neuroprotective effect in STZ-treated rats, indicating the potential of silibinin for the treatment of AD patients with T2DM in future.